Do you believe timely public disclosure of a marketing application would be upon acceptance of that marketing application (sometimes a 60 day process), or do you believe it could be as late as after full review and rejection or approval of the product (sometimes a four to twelve month process)?
If an endpoint was changed in a trial, do you think this would be something that was important to investors?
If trial completion was extended to accommodate a substantial number more events than 233 OS, do you think this would be important to investors?
News 
Market Data 
Discover 
AI
